IMVT · Nasdaq · CIK 0001764013

Immunovant, Inc.

Immunovant, Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 23, 2026. Its EDGAR record lists 52 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2026
—
Net income, FY2026
-$505.6M
Form 4 filings on record, past 12 months
52

Company overview

Legal name (as filed)
Immunovant, Inc.
Ticker
IMVT
SEC Central Index Key (CIK)
0001764013
Business address
DURHAM, NC
State or country of incorporation
DE
Fiscal year ends
March 31
SEC filer category
Large accelerated filer
Position in SEC ticker list
#1202 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Immunovant, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2022n/aFY2023n/aFY2024n/aFY2025n/aFY2026
Net income
-$156.7MFY2022-$211.0MFY2023-$259.3MFY2024-$413.8MFY2025-$505.6MFY2026
IMVT annual results
ItemFY2022
ended Mar 31, 2022		FY2023
ended Mar 31, 2023		FY2024
ended Mar 31, 2024		FY2025
ended Mar 31, 2025		FY2026
ended Mar 31, 2026
Revenue—————
Net income-$156.7M-$211.0M-$259.3M-$413.8M-$505.6M
Diluted EPS-$1.43-$1.71-$1.88-$2.73-$2.77
Total assets$515.6M$405.8M$666.4M$776.2M$957.0M
Cash and equivalents$493.8M$376.5M$635.4M$714.0M$902.1M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

IMVT latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
May 20, 202610-KAnnual report· period Mar 31, 2026Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Sep 3, 20268-KShareholder vote results· period Sep 2, 2026Document · Index
Jul 22, 2026DEF 14ADefinitive proxy statement· period Sep 2, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Immunovant, Inc., by form type:

4 ×24144 ×78-K ×3SCHEDULE 13G/A ×110-Q ×1ARS ×1DEFA14A ×1DEF 14A ×110-K ×1
IMVT recent filings
FiledFormWhat it isOriginal
Oct 23, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 21, 2026Document · Index
Oct 9, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 7, 2026Document · Index
Oct 9, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 7, 2026Document · Index
Oct 9, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 7, 2026Document · Index
Oct 5, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 1, 2026Document · Index
Sep 25, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 23, 2026Document · Index
Sep 3, 20268-KShareholder vote results· period Sep 2, 2026Document · Index
Aug 28, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 28, 2026Document · Index
Aug 21, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 20, 2026Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 6, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 6, 20268-KResults of operations· period Aug 6, 2026Document · Index
Jul 24, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 23, 2026Document · Index
Jul 24, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 24, 2026Document · Index
Jul 24, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 23, 2026Document · Index
Jul 22, 2026ARSARS· period Mar 31, 2026Document · Index
Jul 22, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Jul 22, 2026DEF 14ADefinitive proxy statement· period Sep 2, 2026Document · Index
Jul 10, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 8, 2026Document · Index
Jul 10, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 8, 2026Document · Index
Jul 10, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 8, 2026Document · Index
Jul 6, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 1, 2026Document · Index
Jun 26, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 26, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 26, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 26, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 26, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 26, 2026Document · Index
Jun 26, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 26, 2026Document · Index
Jun 26, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 26, 2026Document · Index
Jun 26, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 26, 2026Document · Index
Jun 26, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 26, 2026Document · Index
Jun 22, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 16, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 15, 2026Document · Index
Jun 15, 2026144Notice of proposed sale of securitiesDocument · Index
May 29, 20264Statement of changes in beneficial ownership (insider trade)· period May 28, 2026Document · Index
May 28, 2026144Notice of proposed sale of securitiesDocument · Index
May 22, 20264Statement of changes in beneficial ownership (insider trade)· period May 20, 2026Document · Index
May 20, 2026144Notice of proposed sale of securitiesDocument · Index
May 20, 202610-KAnnual report· period Mar 31, 2026Document · Index
May 20, 20268-KResults of operations· period May 20, 2026Document · Index

Insider filing activity

52 Form 4 filings appear in Immunovant, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Biological Products, (No Diagnostic Substances)

All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in North Carolina

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001764013 and XBRL company facts. Immunovant, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.